Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.

Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F, Lüscher TF, Arutyunov GP, Motro M, Mori C, Roubert B, Pocock SJ, Ponikowski P.

Eur J Heart Fail. 2017 Apr 24. doi: 10.1002/ejhf.823. [Epub ahead of print]

PMID:
28436136
2.

[Comparative Analysis of the Efficacy and Safety of Rosuvastatin and Original Rosuvastatin].

Bart BY, Luchinkina EE, Gordeev IG, Arutyunov GP, Taratukhin On Behalf Of The Workgroup Of Paritet Trial EO.

Kardiologiia. 2016 Jun;56(6):46-49. Russian.

PMID:
28290847
3.

[The effect of the level of total sodium deposited in the myocardium on its stiffness].

Arutyunov GP, Dragunov DO, Arutyunov GP, Sokolova AV, Papyshev IP, Kildyushov EM, Negrebetsky VV, Fedorova VN.

Ter Arkh. 2017;89(1):32-37. doi: 10.17116/terarkh201789132-37. Russian.

PMID:
28252624
4.

[Impact of the dosing of basic drugs on the risk of rehospitalization in patients with chronic heart failure].

Arutyunov AG, Dragunov DO, Arutyunov GP, Sokolova AV.

Ter Arkh. 2016;88(1):29-34. doi: 10.17116/terarkh201688129-34. Russian.

PMID:
26978606
5.

A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.

Brigandi RA, Johnson B, Oei C, Westerman M, Olbina G, de Zoysa J, Roger SD, Sahay M, Cross N, McMahon L, Guptha V, Smolyarchuk EA, Singh N, Russ SF, Kumar S; PHI112844 Investigators.

Am J Kidney Dis. 2016 Jun;67(6):861-71. doi: 10.1053/j.ajkd.2015.11.021. Epub 2016 Jan 27.

6.

[First Open Study of Syndrome of Acute Decompensation of Heart Failure and Concomitant diseases in Russian Federation: Independent Registry ORAKUL].

Arutyunov AG, Dragunov DO, Arutyunov GP, Rylova AK, Pashkevich DD, Viter KV; ORAKUL.

Kardiologiia. 2015;55(5):12-21. Russian.

PMID:
26615619
7.

2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS).

Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, Brucato A, Gueret P, Klingel K, Lionis C, Maisch B, Mayosi B, Pavie A, Ristić AD, Sabaté Tenas M, Seferovic P, Swedberg K, Tomkowski W, Achenbach S, Agewall S, Al-Attar N, Angel Ferrer J, Arad M, Asteggiano R, Bueno H, Caforio AL, Carerj S, Ceconi C, Evangelista A, Flachskampf F, Giannakoulas G, Gielen S, Habib G, Kolh P, Lambrinou E, Lancellotti P, Lazaros G, Linhart A, Meurin P, Nieman K, Piepoli MF, Price S, Roos-Hesselink J, Roubille F, Ruschitzka F, Sagristà Sauleda J, Sousa-Uva M, Uwe Voigt J, Luis Zamorano J; European Society of Cardiology (ESC).

Eur Heart J. 2015 Nov 7;36(42):2921-64. doi: 10.1093/eurheartj/ehv318. Epub 2015 Aug 29. No abstract available.

8.

[First Open Study of Syndrome of Acute Decompensation of Heart Failure and Concomitant Diseases in Russian Federation: Independent Registry ORAKUL].

Arutyunov AG, Dragunov DO, Arutyunov GP, Rylova AK, Pashkevich DD, Viter On Behalf Of The Study Group KV.

Kardiologiia. 2015 May;55(5):12-21. Russian.

PMID:
28294906
9.

Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.

Brinton EA, Kher U, Shah S, Cannon CP, Davidson M, Gotto AM, Ashraf TB, McCrary Sisk C, Dansky H, Mitchel Y, Barter P; DEFINE Investigators.

J Clin Lipidol. 2015 Jan-Feb;9(1):65-71. doi: 10.1016/j.jacl.2014.10.005. Epub 2014 Nov 4.

PMID:
25670362
10.

Irbesartan in patients with atrial fibrillation.

ACTIVE I Investigators, Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ.

N Engl J Med. 2011 Mar 10;364(10):928-38. doi: 10.1056/NEJMoa1008816.

11.

Safety of anacetrapib in patients with or at high risk for coronary heart disease.

Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P; Determining the Efficacy and Tolerability Investigators.

N Engl J Med. 2010 Dec 16;363(25):2406-15. doi: 10.1056/NEJMoa1009744. Epub 2010 Nov 17.

12.

Ferric carboxymaltose in patients with heart failure and iron deficiency.

Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators.

N Engl J Med. 2009 Dec 17;361(25):2436-48. doi: 10.1056/NEJMoa0908355. Epub 2009 Nov 17.

13.

Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.

Cannon CP, Dansky HM, Davidson M, Gotto AM Jr, Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P; DEFINE investigators.

Am Heart J. 2009 Oct;158(4):513-519.e3. doi: 10.1016/j.ahj.2009.07.028.

PMID:
19781408
14.

Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure.

Arutyunov GP, Kostyukevich OI, Serov RA, Rylova NV, Bylova NA.

Int J Cardiol. 2008 Apr 10;125(2):240-5. doi: 10.1016/j.ijcard.2007.11.103. Epub 2008 Feb 19.

PMID:
18242735

Supplemental Content

Loading ...
Support Center